EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) shares traded -3.27% lower at $17.74 on Wall Street last session.
In accordance with the data, 9 analysts cover EyePoint Pharmaceuticals Inc (NASDAQ:EYPT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $55.00 and a low of $20.00, we find $37.00. Given the previous closing price of $18.34, this indicates a potential upside of 101.74 percent. EYPT stock price is now 138.85% away from the 50-day moving average and 138.47% away from the 200-day moving average. The market capitalization of the company currently stands at $626.40M.
It has been rated a hold by 0 analysts and a buy by 8. Brokers who have rated the stock have averaged $37.63 as their price target over the next twelve months.
With the price target of $20, Mizuho recently initiated with Buy rating for EyePoint Pharmaceuticals Inc (NASDAQ: EYPT).
In other news, EW Healthcare Partners, L.P., 10% Owner sold 20,000 shares of the company’s stock on Sep 01. The stock was sold for $197,982 at an average price of $9.90. Upon completion of the transaction, the 10% Owner now directly owns 3,490,921 shares in the company, valued at $61.93 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 31, 10% Owner EW Healthcare Partners, L.P. sold 78,495 shares of the business’s stock. A total of $804,061 was realized by selling the stock at an average price of $10.24. This leaves the insider owning 3,510,921 shares of the company worth $62.28 million. Insiders disposed of 870,129 shares of company stock worth roughly $15.44 million over the past 1 year. A total of 20.70% of the company’s stock is owned by insiders.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) opened at $19.27 on Tuesday. During the past 12 months, EyePoint Pharmaceuticals Inc has had a low of $2.19 and a high of $22.44. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 2.35, and a quick ratio of 2.28. The fifty day moving average price for EYPT is $7.43 and a two-hundred day moving average price translates $7.44 for the stock.
The latest earnings results from EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.33, beating analysts’ expectations of -$0.51 by 0.18. This compares to -$0.49 EPS in the same period last year. The net profit margin was -235.51% and return on equity was -102.73% for EYPT. The company reported revenue of $15.2 million for the quarter, compared to $10.01 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 51.84 percent. For the current quarter, analysts expect EYPT to generate $9.22M in revenue.
EyePoint Pharmaceuticals Inc(EYPT) Company Profile
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company’s pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
